Amalgamated Bank Sells 303 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Amalgamated Bank lowered its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 2.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,634 shares of the medical research company’s stock after selling 303 shares during the period. Amalgamated Bank’s holdings in Exact Sciences were worth $724,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Asset Management One Co. Ltd. grew its stake in shares of Exact Sciences by 4.3% during the third quarter. Asset Management One Co. Ltd. now owns 68,615 shares of the medical research company’s stock worth $4,674,000 after acquiring an additional 2,837 shares during the last quarter. QRG Capital Management Inc. increased its position in shares of Exact Sciences by 13.8% during the third quarter. QRG Capital Management Inc. now owns 42,377 shares of the medical research company’s stock worth $2,887,000 after purchasing an additional 5,134 shares in the last quarter. Vestor Capital LLC purchased a new stake in Exact Sciences in the 3rd quarter valued at $46,000. Harbor Capital Advisors Inc. purchased a new stake in Exact Sciences in the 3rd quarter valued at $4,825,000. Finally, Chicago Partners Investment Group LLC lifted its stake in shares of Exact Sciences by 1.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock valued at $651,000 after purchasing an additional 158 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Trading Down 3.1 %

Shares of EXAS stock opened at $49.33 on Friday. Exact Sciences Co. has a 52-week low of $40.62 and a 52-week high of $79.62. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. The company has a 50-day simple moving average of $65.83 and a two-hundred day simple moving average of $56.20. The company has a market capitalization of $9.13 billion, a price-to-earnings ratio of -42.16 and a beta of 1.27.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $708.66 million during the quarter, compared to analysts’ expectations of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The company’s revenue was up 12.8% on a year-over-year basis. Research analysts anticipate that Exact Sciences Co. will post -1.08 EPS for the current fiscal year.

Insiders Place Their Bets

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of Exact Sciences stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $70.00, for a total value of $65,030.00. Following the completion of the transaction, the executive vice president now directly owns 12,758 shares of the company’s stock, valued at approximately $893,060. The trade was a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin T. Conroy purchased 19,500 shares of Exact Sciences stock in a transaction dated Wednesday, November 13th. The stock was bought at an average price of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the purchase, the chief executive officer now directly owns 1,074,191 shares of the company’s stock, valued at approximately $55,159,707.85. This trade represents a 1.85 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.36% of the company’s stock.

Analyst Upgrades and Downgrades

EXAS has been the topic of several research reports. Citigroup decreased their target price on Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Canaccord Genuity Group dropped their price target on Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. TD Cowen decreased their price target on Exact Sciences from $90.00 to $82.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Jefferies Financial Group boosted their target price on Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Finally, Craig Hallum dropped their target price on Exact Sciences from $82.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $74.47.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.